Landmark Agreement Among Africa's Leading National Medicines Regulatory Authorities

A landmark agreement has been reached among Africa's leading National Medicines Regulatory Authorities, marking a significant milestone in continental regulatory harmonisation. This agreement aligns with the upcoming transition toward the operationalisation of the African Medicines Agency (AMA), reinforcing the need for harmonised regulatory processes to safeguard health systems across the continent.

H.E. Nardos Bekele-Thomas, CEO of AUDA-NEPAD, emphasized the significance of this agreement in advancing regulatory cooperation and mutual recognition among African countries. The agreement represents a major step forward in reducing regulatory fragmentation and improving access to quality medicines across Africa.

Key Elements of the Agreement:

• Mutual recognition of regulatory decisions among participating countries
• Recognition of Good Manufacturing Practice (GMP) inspection reports
• Harmonised registration requirements and procedures
• Joint assessment and inspection mechanisms
• Reduced regulatory duplication and processing times
• Support for the African Continental Free Trade Area (AfCFTA)

Participating Regulatory Authorities:

The agreement brings together some of Africa's most advanced regulatory authorities, including representatives from South Africa (SAHPRA), Ghana (Ghana FDA), Tanzania (TMDA), Kenya (PPB), and other leading NRAs across the continent.

Impact on African Healthcare:

This landmark agreement will enable faster market access for quality-assured medicines, reduce costs for pharmaceutical manufacturers, and improve regulatory efficiency across participating countries. It represents a critical step toward the full operationalisation of the African Medicines Agency and the realisation of the African Union's vision for harmonised pharmaceutical regulation.

The agreement builds on years of work under the African Medicines Regulatory Harmonisation (AMRH) program and demonstrates the commitment of African countries to strengthening their regulatory systems and improving access to quality medicines for their populations.